World's largest genomics sequencing company.

Small molecule innovative drug company. KRAS G12C inhibitor and other targeted oncology drugs. Backed by top VCs.

Apoptosis-targeted drug discovery. BCL-2 inhibitor olverembatinib for leukemia. First Chinese-developed BCL-2 inhibitor.

Pioneer in epigenetic drug discovery. Chidamide (HDAC inhibitor) for cancer. Novel mechanism drugs from proprietary platform.

Major pharma company with innovative drug R&D. Oncology, anti-infection, and cardiovascular. Strong generics + growing innovative pipeline.

China's innovative drug leader. Oncology, autoimmune, metabolic diseases. 60+ innovative drugs in pipeline. Transitioning from generics to innovation.

Global CRO/CDMO giant. Small molecule drug discovery and development services. Serves 6,000+ global clients including all top 20 pharma.

World's leading CDMO for biologics. End-to-end biologics development and manufacturing. 700+ projects for global clients.

CRO/CDMO company. Building block library for drug discovery. Flow chemistry and biocatalysis platforms. Partner to global pharma.

China's largest medical device company. Patient monitoring, IVD diagnostics, and medical imaging. Global presence in 190+ countries.